Table of Contents
What Is Sickle Cell Disease?
Sickle cell disease (SCD) refers to a group of inherited disorders involving a mutation in the β-globin allele, resulting in the production of sickle hemoglobin (Hb S). It is the most prevalent genetic disorder globally, with approximately 100,000 individuals affected in the United States. Vaso-occlusive pain crises are the hallmark of SCD, while acute chest syndrome is a leading cause of hospitalization and mortality.
The fundamental process in SCD is the polymerization of HbS at low oxygen levels, leading to red blood cell sickling, vessel blockages, tissue damage, and hemolysis. Other contributing factors include inflammation, increased cell adhesion, platelet activation, clotting tendencies, nitric oxide deficiency, and vascular issues, all contributing to severe multi-organ complications. Higher rates of morbidity and mortality are observed, especially in individuals homozygous for Hb S.
In contrast, sickle cell trait (SCT) denotes individuals carrying one sickle cell gene from one parent and a normal gene from the other. Though the clinical significance of SCT is still under investigation, there are associations with conditions like chronic kidney disease, exertional rhabdomyolysis, and venous thromboembolism. Coronavirus Disease 2019 (COVID-19) is caused by the severe acute respiratory coronavirus 2 (SARS-COV-2) and has evolved into a global pandemic.
By August 2022, over 590 million cases and 6.4 million deaths, including over 1 million in the United States alone, had been reported. Available data on COVID-19 outcomes among individuals with SCD and SCT is limited, mostly consisting of case series reports, retrospective studies, or registry analyses prone to reporting biases. Nevertheless, these studies have provided valuable insights into the impacts of COVID-19 on individuals with SCD and SCT. This article explains the safety of the COVID-19 vaccine for patients with sickle cell anemia.
Is COVID-19 Vaccine Safe and Effective for Individuals with Sickle Cell Disease?
Our study findings reveal an elevated risk of hospitalization, pain, and pneumonia due to COVID-19 among individuals with sickle cell disease compared to black individuals without sickle cell disease or trait, even after adjusting for age, sex, and other preexisting conditions. Similarly, it has been observed that COVID-19 outcomes for individuals with sickle cell trait, after adjusting for demographic and clinical characteristics, do not significantly differ from those of black individuals without sickle cell disease or trait.
The following are the highlights of the safety of the COVID-19 vaccine in patients with sickle cell anemia:
-
Our results highlight that sickle cell patients face a heightened risk of severe infection if they contract COVID-19.
-
These findings align with the understanding that individuals with sickle cell disease are prone to experiencing severe illness with viral infections due to specific pathophysiological changes linked to sickle cell disease, such as those seen in influenza.
-
Moreover, infections can exacerbate sickle cell disease-related complications like pain and acute chest syndrome.
-
Furthermore, after accounting for relevant comorbidities, the findings support the notion that the severity of COVID-19 can be attributed to sickle cell disease.
-
The observed death rate among those with sickle cell disease in our study (3.2%) mirrors that reported by the largest international COVID-19 sickle cell registry (3.1%). Even after matching based on age, sex, and other comorbidities, we found no disparity in death rates between the two groups.
-
This suggests that mortality rates do not significantly differ between individuals with sickle cell disease and the general black population, with similar rates of comorbidities and end-organ damage.
-
It further suggests that organ damage may elevate the risk of COVID-19 mortality, whether due to sickle cell disease or other causes.
-
However, it is notable that, despite individuals with sickle cell disease experiencing more severe COVID-19-related symptoms,
-
The fatality rate between the matched groups did not significantly differ. This could be attributed to individuals with sickle cell disease being more inclined to seek medical care due to their known risk of sickle cell disease complications during infections compared to black individuals without sickle cell disease.
-
Future research is warranted to explore whether access to care or prompt receipt of COVID-19 treatment influences outcomes across the population.
-
Some studies also found that individuals with sickle cell trait exhibit COVID-19 outcomes similar to those of black individuals without sickle cell disease or trait.
-
Recent studies have shown that diagnostic codes for sickle cell traits are highly specific but have low sensitivity.
-
Given universal newborn screening in the United States, it is surprising that trait status remains undocumented for many individuals.
-
Systematic reporting of trait status and its inclusion in medical records can further our understanding of risks and outcomes for this population, irrespective of COVID-19.
Several noted comorbidities, such as a history of stroke and impaired renal function, may be linked to the natural course of sickle cell disease. This underscores the importance of standardized electronic health record data and data sharing among institutions, particularly in these urgent times. Our findings underscore the significance of knowing a patient's medical history and sickle cell disease status in understanding outcome risks and guiding COVID-19 management. The risks associated with underlying comorbidities may also vary among different population groups or settings. Future research exploring these risks in specific patient groups can further inform clinical care.
Regardless of sickle cell disease or trait status, there is a need to examine health equity across races, not only concerning COVID-19 management but throughout an individual's lifespan. Health disparities can impact the prevalence and management of comorbidities, increasing the risk of poor outcomes not just from COVID-19 but also from other conditions. Structural and systemic racism within society and healthcare systems can also affect the management of sickle cell disease, other comorbidities, and COVID-19, resulting in adverse health outcomes.
Existing literature on COVID-19 in sickle cell disease and trait mostly consists of case reports or series or lacks a comparative group. Only one study from France has compared COVID-19 outcomes among individuals with sickle cell disease versus the general population. However, this study lacked the statistical power to detect differences and was limited to the inpatient setting. Our study, to our knowledge, is the first to compare COVID-19 outcomes, including hospitalization, symptoms, and death, among individuals with sickle cell disease/trait versus black individuals without sickle cell disease or trait.
Based on a large sample, our analyses account for many comorbidities associated with severe COVID-19 illness, providing insights into the risks attributable to sickle cell disease and trait specifically.
In summary, the data provide evidence that sickle cell disease poses an additional risk of severe COVID-19 illness and hospitalization, even after adjusting for age, sex, and other preexisting conditions. However, the death rate between sickle cell disease and black individuals without sickle cell disease/trait, matched for age, sex, and preexisting comorbidities, did not significantly differ. We found no significant differences in COVID-19 outcomes between sickle cell trait and black individuals without sickle cell trait/disease after balancing for age, sex, and other preexisting conditions.
Conclusion
Despite frequent visits to the emergency department and hospitalizations, many individuals with sickle cell disease (SCD) and COVID-19 only experience mild to moderate illness, with vaso-occlusive pain crises being the most prevalent presentation and complication. Factors that increase the risk of severe COVID-19 among individuals with SCD include advanced age, previous visits to acute care for pain management, and pre-existing end-organ complications such as heart failure, chronic kidney disease, pulmonary hypertension, and stroke. While hemoglobin SC disease is typically considered less severe than other forms of SCD, recent studies suggest that it may lead to worse outcomes in COVID-19, possibly due to higher rates of venous thromboembolism. The sickle cell trait (SCT) has also been linked to variations in COVID-19 outcomes, particularly among those with existing conditions like chronic kidney disease.
